Precigen (PGEN) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Zai Lab (ZLAB) over the past year, gaining 136.0% versus a loss of 26.4%. Over five years, PGEN leads with a +63.4% price change compared with -75.7% for ZLAB. Zai Lab is the larger company by market cap ($2.79 billion vs $2.72 billion), about 1.0 times the size, while Precigen is growing revenue faster (+146.7% vs +15.3%).
Zai Lab converts more of its revenue into profit, with a net margin of -38.1% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | ZLAB |
|---|---|---|
| Share price | $7.60 | $24.81 |
| Market cap | $2.72B | $2.79B |
| 1-day change | +0.80% | -1.98% |
| YTD return | +81.82% | +40.65% |
| 1-year return | +136.02% | -26.36% |
| 5-year return | +63.44% | -75.68% |
| EPS (TTM) | $-1.04 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $460.16M |
| Revenue growth (YoY) | +146.73% | +15.33% |
| Net income (latest FY) | $-250.64M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | -1141.13% | -49.86% |
| Net margin | -2588.21% | -38.15% |
| 52-week high | $8.98 | $33.65 |
| 52-week low | $2.99 | $15.96 |
| Distance from 52-week high | -15.37% | -26.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +79.61% | +33.58% |
| Average volume | 5.02M | 944.83K |
| Shares outstanding | 358.04M | 112.27M |
| Employees | 160 | 1,784 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed ZLAB by 162.4 percentage points over the past year.
- Zai Lab is more profitable, keeping -38.1 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +15.33%).
- The two companies sit in different sectors: Precigen in Healthcare and Zai Lab in Health Care.
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
PGEN vs ZLAB FAQ
Which is bigger, Precigen or Zai Lab?
Zai Lab (ZLAB) is larger, with a market capitalization of $2.79B compared with $2.72B for Precigen (PGEN).
Which stock has performed better over the past year, PGEN or ZLAB?
PGEN returned +136.02% over the past 12 months, compared with -26.36% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Zai Lab in the same industry?
No. Precigen is in the Healthcare sector, while Zai Lab is in Health Care.